Studies conducted before the introduction of ICIs in melanoma treatment have demonstrated that patients diagnosed with a primary melanoma with inherited MC1R variants have improved melanoma‐specific survival compared to patients with consensus MC1R alleles (Davies et al. 2012; Taylor et al. 2015). Here, MC1R is linked to melanoma.